{
    "clinical_study": {
        "@rank": "48568", 
        "acronym": "GAMBIT", 
        "arm_group": [
            {
                "arm_group_label": "IP", 
                "arm_group_type": "Experimental", 
                "description": "Irinotecan 65mg/m\u00b2 D1 and D8 q21 days plus Cisplatin 60mg/m\u00b2 D1 q 21 days, until disease progression or unacceptable toxicity, with standard hydration and antiemetics."
            }, 
            {
                "arm_group_label": "GC", 
                "arm_group_type": "Active Comparator", 
                "description": "Gemcitabine 1000mg/m\u00b2 D1 and D8 every 21 days plus cisplatin 25mg/m\u00b2 D1 and D8 every 21 days, until disease progression or unacceptable toxicity, with standard hydration and antiemetics."
            }
        ], 
        "brief_summary": {
            "textblock": "To evaluate safety and efficacy of the combination cisplatin plus irinotecan in the\n      treatment of biliary tract cancer."
        }, 
        "brief_title": "GAMBIT Trial: Cisplatin Plus Irinotecan in the Treatment of Gallbladder or Biliary Tract Cancer", 
        "completion_date": {
            "#text": "July 2015", 
            "@type": "Anticipated"
        }, 
        "condition": "Biliary Cancer", 
        "condition_browse": {
            "mesh_term": "Biliary Tract Neoplasms"
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  biopsy-proven gallbladder or biliary tract cancer;\n\n          -  Recurrent, metastatic or unresectable disease;\n\n          -  Chemo-na\u00efve.\n\n          -  Not candidates to curative-intent treatment, such as surgery or radiation-therapy;\n\n          -  Measurable disease according to RECIST 1.1;\n\n          -  ECOG 0-2;\n\n          -  Adequate hematologic and biochemistry tests;\n\n          -  Creatinine clearance >= 60ml/min.\n\n        Exclusion Criteria:\n\n          -  Known hypersensibility or previous therapy with cisplatin, gemcitabine or irinotecan;\n\n          -  Chronic immunosuppressive therapy;\n\n          -  Known CNS metastasis;\n\n          -  Previous diagnosis of other cancer;\n\n          -  Chronic or acute active infection, except asymptomatic HIV infection;\n\n          -  Active bleeding;\n\n          -  Any severe medical condition;\n\n          -  Pregnant or lactating women, or with childbearing potential;"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "48", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "May 14, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01859728", 
            "org_study_id": "GAMBIT201201"
        }, 
        "intervention": [
            {
                "arm_group_label": "IP", 
                "description": "Given in association with standard hydration and anti-emetics.", 
                "intervention_name": "Irinotecan", 
                "intervention_type": "Drug", 
                "other_name": "Irinotecan 65mg/m\u00b2 D1 and D8 q21 days, until disease progression or unacceptable toxicity."
            }, 
            {
                "arm_group_label": "IP", 
                "description": "Given in association with standard hydration and anti-emetics.", 
                "intervention_name": "Cisplatin", 
                "intervention_type": "Drug", 
                "other_name": "Cisplatin 60mg/m\u00b2 D1 q 21 days, until disease progression or unacceptable toxicity."
            }, 
            {
                "arm_group_label": "GC", 
                "description": "Given in association with standard hydration and anti-emetics.", 
                "intervention_name": "Cisplatin", 
                "intervention_type": "Drug", 
                "other_name": "Cisplatin 25mg/m\u00b2 D1 and D8 every 21 days, until disease progression or unacceptable toxicity. , with standard hydration and antiemetics."
            }, 
            {
                "arm_group_label": "GC", 
                "description": "Given in association with standard hydration and anti-emetics.", 
                "intervention_name": "Gemcitabine", 
                "intervention_type": "Drug", 
                "other_name": "Gemcitabine 1000mg/m\u00b2 D1 and D8 every 21 days, until disease progression or unacceptable toxicity."
            }
        ], 
        "intervention_browse": {
            "mesh_term": [
                "Antiemetics", 
                "Gemcitabine", 
                "Irinotecan", 
                "Cisplatin"
            ]
        }, 
        "is_fda_regulated": "No", 
        "keyword": [
            "biliary cancer", 
            "irinotecan", 
            "cisplatin", 
            "gemcitabine"
        ], 
        "lastchanged_date": "April 17, 2014", 
        "location": {
            "contact": {
                "email": "lucasvsantos@yahoo.com", 
                "last_name": "Lucas V. dos Santos, M.D.", 
                "phone": "+551781544670"
            }, 
            "contact_backup": {
                "email": "kathia.abdalla@hcancerbarretos.com.br", 
                "last_name": "Kathia C Abdalla, MD", 
                "phone": "+551733216600", 
                "phone_ext": "6829"
            }, 
            "facility": {
                "address": {
                    "city": "Barretos", 
                    "country": "Brazil", 
                    "state": "SP", 
                    "zip": "14784400"
                }, 
                "name": "Barretos Cancer Hospital"
            }, 
            "investigator": [
                {
                    "last_name": "Kathia C Abdalla, MD", 
                    "role": "Principal Investigator"
                }, 
                {
                    "last_name": "Arinilda C Bragagnoli, MD", 
                    "role": "Sub-Investigator"
                }
            ], 
            "status": "Recruiting"
        }, 
        "location_countries": {
            "country": "Brazil"
        }, 
        "number_of_arms": "2", 
        "official_title": "Estudo Cl\u00ednico de Fase II, Randomizado, Avaliando a combina\u00e7\u00e3o de Cisplatina e Irinotecano no Tratamento de Primeira Linha do Carcinoma da ves\u00edcula Biliar, Vias Biliares Intra ou Extra-hep\u00e1ticas irressec\u00e1vel ou metast\u00e1tico (ESTUDO GAMBIT) (GAMBIT Trial: A Randomized,Non-comparative, Open-label Clinical Trial Evaluating Cisplatin Plus Irinotecan in the Treatment of Gallbladder or Biliary Tract Cancer)", 
        "other_outcome": {
            "description": "The following biomarkers will be tested by immunohistochemistry: human equilibrative nucleoside transporter (hENT), X-ray repair cross-complementing protein 1 (XRCC1), Excision repair cross-complementing rodent repair deficiency, complementation group 1 (ERCC1) e mLH1. Then we will correlate them with efficacy end-points using non-parametric test.", 
            "measure": "Biomarker evaluation", 
            "safety_issue": "No", 
            "time_frame": "Baseline"
        }, 
        "overall_contact": {
            "email": "lucasvsantos@yahoo.com", 
            "last_name": "Lucas V dos Santos, MD", 
            "phone": "+5517-81544670"
        }, 
        "overall_contact_backup": {
            "email": "kathia.abdalla@hcancerbarretos.com.br", 
            "last_name": "Kathia C Abdalla, MD", 
            "phone": "+551733216600", 
            "phone_ext": "6829"
        }, 
        "overall_official": [
            {
                "affiliation": "Barretos Cancer Hospital", 
                "last_name": "Lucas V dos Santos, MD", 
                "role": "Study Chair"
            }, 
            {
                "affiliation": "Barretos Cancer Hospital", 
                "last_name": "Kathia C Abdalla, MD", 
                "role": "Principal Investigator"
            }, 
            {
                "affiliation": "Barretos Cancer Hospital", 
                "last_name": "Joao Paulo S N Lima, MD, PhD", 
                "role": "Study Director"
            }
        ], 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": "Brazil: National Committee of Ethics in Research", 
            "has_dmc": "Yes"
        }, 
        "phase": "Phase 2", 
        "primary_completion_date": {
            "#text": "February 2015", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "description": "The overall response rate will measure the number of subjects with complete or partial response as best response during the entire treatment, over the total number of subjects, for each arm. The response will be evaluated according to RECIST 1.1.", 
            "measure": "Overall Response Rate", 
            "safety_issue": "No", 
            "time_frame": "Up to 24 weeks from randomization"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01859728"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "description": "We will measure the number of subjects without progressive disease (complete response, partial response or stable disease) or any-cause death, whichever came first. For each patient, PFS will be calculated from randomization until progressive disease. Disease progression means radiologic progression per RECIST 1.1 or any-cause death. PFS will also be analysed with log-rank test, and reported as HR with respective 95% CI and p value, and median PFS will be estimated with kaplan-meyer method. All calculations will be performed 6 months after the last patient recruited. Also, the PFS rate at one and two years will be calculated.", 
                "measure": "Progression-Free Survival (PFS)", 
                "safety_issue": "No", 
                "time_frame": "6mo after the last enrolled patient"
            }, 
            {
                "description": "We will measure the number of subjects without any-cause death. For each patient, OS will be calculated from randomization until death. OS will also be analysed with log-rank test, and reported as HR with respective 95% CI and p value, and median OS will be estimated with kaplan-meyer method. All calculations will be performed 6 months after the last patient recruited. Also, the survival rate at one and two years will be calculated.", 
                "measure": "Overall Survival (OS)", 
                "safety_issue": "No", 
                "time_frame": "6mo after the last enrolled patient"
            }, 
            {
                "description": "The disease control rate will measure the number of subjects with complete or partial response, or disease stabilization as best response during the entire treatment, over the total number of subjects, for each arm. The response will be evaluated according to RECIST 1.1.", 
                "measure": "Disease Control Rate", 
                "safety_issue": "No", 
                "time_frame": "Up to 6 weeks from randomization"
            }, 
            {
                "description": "Safety and tolerability will be assessed using NCI CTCAE v3. The number of patients in each arm experiencing any grade Adverse Events (for each AE) and Serious AE (SAE) over the total number of subjects will be measured, and the proportion of patients experiencing AE in each arm will be compared using uncorrected chi-sq test. AE will be recorded in baseline and in each visit, and the worst grade AE will be considered. Each AE will be classified in grades 1-2, 3-4 and SAE.", 
                "measure": "Safety", 
                "safety_issue": "Yes", 
                "time_frame": "6 mo after the last enrolled patients"
            }
        ], 
        "source": "Barretos Cancer Hospital", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Hospital de Cancer de Barretos - Fundacao Pio XII", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "January 2013", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "April 2014"
    }
}